This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.
With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.
As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity. A prime example of strategic spending is Merck & Co./MSD,
While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.
Biopharma should pay special attention to this. Biopharma companies that bring patients together in-person can create a sense of belonging and support that is often missing in the digital realm. Social Connections and Mortality from all Causes and from Cardiovascular Disease: Prospective Evidence from Eastern Finland.”
In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.
We at The Marketing Advantage have been designing call plans based on sales, opportunity, potential, maintenance and growth for the biopharma industry for over 30 years. In fact, in one case, the prescriber was the spouse of a competitive sales representative. Why Don’t Sales Representatives Follow Call Plans?
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
Competition is imminent as the CheckMate-76K trial evaluating Bristol-Myers Squibb’s Opdivo in stage IIB-C melanoma patients is also poised to enter this setting. This novel antibody-drug conjugate (ADC)ADC faces much competition, should it be approved. Abstract LBA52. Abstract 944P.
Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.
The result was a plethora of patient infringement lawsuits , with several cases being filed that included Moderna, Pfizer/BioNTech, Alnylam Pharmaceuticals, Arbutus Biopharma, and Genevant Sciences on different sides of the court. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies.
Vetter Pharma-Fertigung GmbH & Co KG is contracted for the parenteral manufacture and packaging for the vascular endothelial growth factor (VEGF) inhibitor, while Biogen and KBI Biopharma are producing the biologic API. Baxter Biopharma Solutions is contracted for the parenteral manufacture and packaging of Enhertu.
GC Biopharma is also running a Phase III trial for its live-attenuated vaccine GC-3107A to replace BCG. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.
At $48 a share for the South San Francisco,California-based biopharma, Lilly is paying a 40% premium on top of the 30-day average trading price. GlobalData is the parent company of Pharmaceutical Technology DICE’s novel oral therapeutic candidates positioned it as an attractive prospect for acquisition.
This year, competition in the obesity therapeutic landscape has ramped up as biotechs aim to follow the success of blockbuster drugs from Novo Nordisk , Eli Lilly and more. In the panel, Melanie Senior, a biopharma reporter at Nature Biotech also pointed out reimbursement issues for obesity drugs.
This is an exciting prospect: oncology, and immuno-therapy in particular, is a driving force behind biotech R&D, with new cancer therapies and molecules accounting for nearly 40% 1 of the industry’s development pipeline. SHL Medical knows that widening the use of autoinjectors for volumes of up to 5.0 References 1.
Synthetic biology biopharma Biostar Pharma announced is ready to advance its utidelone injectable (UTD1) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the US Food and Drug Administration (FDA) for the study.
The proposed facility would play a vital role in fulfilling demand in the Asia Pacific region while representing an important hub for further biopharma industry development in South Korea.” We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Baxter Biopharma Solutions, Fareva SA, BSP Pharmaceuticals SpA, and Takeda Pharmaceuticals are manufacturing the parenteral portion of the ADC. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Baxter Biopharma Solutions has been contracted for the ADC’s parenteral manufacture and packaging. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content